PASS
Task-ID: KMX-003
Head-SHA: c380c6971f6d59f9bd921d5007286e48a430af3c
Role: minimax

1: OK - allocation.py uses per-level pg_advisory_xact_lock keys (910001/910002/910003) around max+1 from kmx.registry only; no sequences, no new tables, no random ids; CI-gated 8-thread uniqueness test present.
2: OK - repository.py adds insert_kmx, insert_external_identifier, insert_name, insert_containment (with ordinal/relationship), and existing_containment using the existing self._connection.execute pattern; resolver is untouched and remains read-only.
3: OK - build_ingredient refuses MIN with MappingExceptionBoundaryError, enforces allowed_levels, mints PINs as their own KMX-ING, and links via kmx.contains(precise_ingredient, container=base, member=PIN) only when relationship_proven; unproven PINs keep identity with no edge.
4: OK - build_clinical_drug validates every member is a resolved ingredient, mints brand-neutral formulations, emits deterministic ordinals 1..n in caller order, and the three-variant test proves distinct strengths/release stay distinct; reuse is exact-identifier only.
5: OK - build_product gates on APPROVED_PRODUCT_CREATORS plus exact regulator system+value plus resolved CD members; SBD/brand/wrong-lane/missing-id all raise PRODUCT_IDENTITY_UNPROVEN; products contain CDs; owning_transaction provides BEGIN/inserts/COMMIT/ROLLBACK and the rollback test proves atomicity.
Findings: Allocation, builders, repository write surface, and the CI-gated concurrency test are coherent and satisfy the KMX-003 contract. The strict product proof gate, PIN/base association rules, and atomic transaction scope are all enforced and covered by tests.
Checks: All five requirements verified against the diff; no sequences, no new permanent tables, no renumbering, no name-based reuse, and the rollback test demonstrates atomic failure semantics.
